NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis $10.32 -0.17 (-1.62%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About ABIVAX Société Anonyme Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABIVAX Société Anonyme alerts:Sign Up Key Stats Today's Range$10.27▼$10.5050-Day Range$8.97▼$12.7152-Week Range$8.75▼$17.02Volume10,449 shsAverage Volume92,681 shsMarket Capitalization$653.20 millionP/E RatioN/ADividend YieldN/APrice Target$36.50Consensus RatingModerate Buy Company OverviewABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, ABIVAX Société Anonyme Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks67th Percentile Overall ScoreABVX MarketRank™: ABIVAX Société Anonyme scored higher than 67% of companies evaluated by MarketBeat, and ranked 396th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has received no research coverage in the past 90 days.Read more about ABIVAX Société Anonyme's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.86) per share.Price to Book Value per Share RatioABIVAX Société Anonyme has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently decreased by 16.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.41% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently decreased by 16.53%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.29 News SentimentABIVAX Société Anonyme has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added ABIVAX Société Anonyme to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ABIVAX Société Anonyme's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest UpdateOctober 28 at 1:21 AM | americanbankingnews.comAbivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene RegulationOctober 7, 2024 | globenewswire.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 31, 2024 | Porter & Company (Ad)Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's DiseaseOctober 3, 2024 | globenewswire.comAbivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label MaintenanceOctober 3, 2024 | globenewswire.comAbivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024September 26, 2024 | globenewswire.comAbivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse ModelSeptember 25, 2024 | globenewswire.comABIVAX Société Anonyme (0RA9.L)September 18, 2024 | nz.finance.yahoo.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of 2024. Since then, ABVX stock has decreased by 3.6% and is now trading at $10.32. View the best growth stocks for 2024 here. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. Who are ABIVAX Société Anonyme's major shareholders? ABIVAX Société Anonyme's top institutional investors include abrdn plc (0.50%) and Rosalind Advisors Inc. (0.22%). How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ABIVAX Société Anonyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABIVAX Société Anonyme investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX) and Howard Hughes (HHH). Company Calendar Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$16.00 Potential Upside/Downside+252.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.48 Current Ratio3.04 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book3.08Miscellaneous Outstanding Shares63,295,000Free FloatN/AMarket Cap$656.37 million OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:ABVX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.